SCHEMBL3523171

SCHEMBL3523171

COc1ccc(CN2CCCCCC=CC3CC3(C(N)=O)NC(=O)C3CC(O)CN3C2=O)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 1/20 0.34
▸ MMP13 P45452 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ CTSB P07858 1/20 0.33
▸ OPRM1 P35372 3/20 0.33
▸ OPRL1 P41146 1/20 0.33
▸ SIRT2 Q8IXJ6 1/20 0.33
▸ SIRT1 Q96EB6 1/20 0.33
▸ HDAC1 Q13547 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ DPP4 P27487 1/20 0.32
▸ ADRB3 P13945 1/20 0.31
▸ ADRA2B P18089 1/20 0.31
▸ ADRA2C P18825 1/20 0.31
▸ HRH3 Q9Y5N1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16628772 0.93 ADRB3 (0.36) MMP1MMP13ALOX15GAACTSB
SCHEMBL16628773 0.93 ADRB3 (0.36) MMP1MMP13ALOX15GAACTSB
SCHEMBL8239738 0.91 ALDH1A1 (0.36) MMP1MMP13ALOX15GAACTSB
SCHEMBL995885 0.91 ALDH1A1 (0.36) MMP1MMP13ALOX15GAACTSB
SCHEMBL19215370 0.91 ALDH1A1 (0.36) MMP1MMP13ALOX15GAACTSB
SCHEMBL10156974 0.91 ALDH1A1 (0.36) MMP1MMP13ALOX15GAACTSB
SCHEMBL995888 0.91 ALDH1A1 (0.36) MMP1MMP13ALOX15GAACTSB
SCHEMBL3526970 0.88 ADRB3 (0.32) MMP1MMP13ALOX15GAACTSB
SCHEMBL8246317 0.88 CTSB (0.46) MMP1MMP13ALOX15GAACTSB
SCHEMBL15159925 0.87 CYP3A4 (0.38) MMP1MMP13ALOX15CTSBOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666834-B2 Macrocyclic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-02-23 — — US disclosed
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105302-A1 Macrocylic Inhibitors of Hepatitis C Virus HCCS, CBR1, CYP2B6 MMP1 3760/4885MMP13 3916/4885ALOX15 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback